For how we live.
A section 564 declaration, prompted by a July determination from the Secretary of War, opens the door to authorising unapproved drugs for acute pain in combat and CBRN casualties.
A 411,000-patient claims study found adults on GLP-1 drugs who started oxycodone had more severe constipation and bowel obstruction at 30 days than those starting hydrocodone or tramadol.
Stargardt disease, the most common inherited macular dystrophy, has no approved treatment. In the 50-patient TEASE-1 trial, gildeuretinol slowed atrophic lesion growth by a fraction of a millimetre a year.
In an early-phase trial of 136 previously treated patients, daraxonrasib produced responses in 31–37% depending on dose — but 54% had a serious side effect, and this is a phase 1–2 study.
A draft replacing a 2003 document would extend hepatic-impairment dosing studies to biologic drugs and to drug effects, not just blood levels. It is open for comment before the agency finalises it.
At recommended doses it is one of the best-tolerated painkillers. The liver harm concentrates at high doses, and half of the failure cases are unintentional, often from combining products.
Matched against DPP-4 inhibitors, GLP-1 users had slightly more diabetic retinopathy and more retinopathy procedures. Vision impairment and blindness did not differ — and the coding for those is poor.
Users were slightly less likely than non-users to attempt suicide in the two to four years after treatment. The FDA's 2005 boxed warning stands, and the analysis cannot explain the direction of the finding.
Observational studies had linked proton pump inhibitors to fractures, dementia, kidney disease and more. A randomised trial collected all of those outcomes and found only enteric infections.
Across studies, current NSAID use was tied to about a 73% higher odds of acute kidney injury, more in older people and those with existing kidney disease. The combination with two blood-pressure drugs is the real hazard.
A European task force argued the first-generation drugs sold over the counter should not be. On symptom relief the newer ones differ from each other too — and the most familiar performed worst.
Two Cochrane reviews back scopolamine and first-generation antihistamines for preventing motion sickness. Both found the same gap: not a single randomised trial has looked at relieving symptoms already under way.
Expert guidelines back antibiotics for moderate-to-severe cases and simple measures for mild ones. The popular Pepto-Bismol prevention habit rests on 1980s data — and a 2025 trial could not confirm it worked.
The older oral preventives managed 0.44 to 1.4. The larger change is that the new drugs work in people the old ones failed, and are tolerated well enough to stay taken.
A Cochrane review of 64 trials found acetazolamide cut the risk of acute mountain sickness by about half. It is a genuine drug effect, not a folk remedy — and it is a prescription decision, not a supplement.
In February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
Of 1,363 evaluable patients matched to drugs by tumor genetics, 7% became exceptional responders. Activity across all 37 drugs was modest, and severe side effects hit over a quarter.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
An Israeli case-control study found an apparent fourfold risk that vanished once the year before diagnosis was excluded. A Nordic study of 17,232 cancers found no association at all.
Pooling 151 studies and 58,534 participants across 30 drugs, researchers ranked antidepressants by physiological side effects rather than efficacy. Some drugs raised cholesterol while reducing body weight.
Two trials showed more deaths on voxelotor than placebo. The registry data that triggered the 2024 precautionary suspension did not confirm the original signal — the trials did something worse.